ArticleNeuropsychiatric disease and treatment2009
New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists.
Article in Neuropsychiatric disease and treatment, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 89 citations in OpenAlex.
- Melatonin and sleep: Exploring its role in regulating the circadian rhythm and sleep-wake cycle.Journal of family medicine and primary care · 2026Review
- Detailed Review of Melatonin and its Role in Managing the Symptoms of Depression.Current molecular medicine · 2026Review
- Gut Bacterial Metabolites from Tryptophan and Phenylalanine Induce Melatonin Synthesis and Extend Sleep Duration in Mice.ACS omega · 2024Article
- Neuroprotective Effect of WhiteFoods (Basel, Switzerland) · 2023Article
- Melatonin for Insomnia in Medical Inpatients: A Narrative Review.Journal of clinical medicine · 2022Review
- Redox Biology of Melatonin: Discriminating Between Circadian and Noncircadian Functions.Antioxidants & redox signaling · 2022Review
- Long-term environmental exposure of darkness induces hyperandrogenism in PCOSFrontiers in cell and developmental biology · 2022Article
- Utilization of redox modulating small molecules that selectively act as pro-oxidants in cancer cells to open a therapeutic window for improving cancer therapy.Redox biology · 2021Review
- Divergent Importance of Chronobiological Considerations in High- and Low-dose Melatonin Therapies.Diseases (Basel, Switzerland) · 2021Review
- Efficacy and safety of supplemental melatonin for delayed sleep-wake phase disorder in children: an overview.Sleep medicine: X · 2020Review
- Review
- Electroacupuncture for primary insomnia: Protocol for a systematic review and meta-analysis.Medicine · 2018Article
- Chronomedicine and type 2 diabetes: shining some light on melatonin.Diabetologia · 2017Review
- Electroacupuncture for insomnia disorder: study protocol for a randomized controlled trial.Trials · 2017Article
- A Review of Melatonin, Its Receptors and Drugs.The Eurasian journal of medicine · 2016Review
- Activation of Melatonin Receptors Reduces Relapse-Like Alcohol Consumption.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015Article
- Profile of suvorexant in the management of insomnia.Drug design, development and therapy · 2015Review
- Agomelatine or ramelteon as treatment adjuncts in glioblastoma and other M1- or M2-expressing cancers.Contemporary oncology (Poznan, Poland) · 2015Article
- Protecting the melatonin rhythm through circadian healthy light exposure.International journal of molecular sciences · 2014Review
- Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders.International journal of molecular sciences · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypnotic effects of melatonin and melatoninergic drugs are mediated via MT(1) and MT(2) receptors, especially those in the circadian pacemaker, the suprachiasmatic nucleus, which acts on the hypothalamic sleep switch. Therefore, they differ fundamentally from GABAergic hypnotics. Melatoninergic agonists primarily favor sleep initiation and reset the circadian clock to phases allowing persistent sleep, as required in circadian rhythm sleep disorders. A major obstacle for the use of melatonin to support sleep maintenance in primary insomnia results from its short half-life in the circulation. Solutions to this problem have been sought by developing prolonged-release formulations of the natural hormone, or melatoninergic drugs of longer half-life, such as ramelteon, tasimelteon and agomelatine. With all these drugs, improvements of sleep are statistically demonstrable, but remain limited, especially in primary chronic insomnia, so that GABAergic drugs may be indicated. Melatoninergic agonists do not cause next-day hangover and withdrawal effects, or dependence. They do not induce behavioral changes, as sometimes observed with z-drugs. Despite otherwise good tolerability, the use of melatoninergic drugs in children, adolescents, and during pregnancy has been a matter of concern, and should be avoided in autoimmune diseases and Parkinsonism. Problems and limits of melatoninergic hypnotics are compared.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.